Power Law company profile

Bioverativ

Biotech & Life Sciences · Waltham, United States · Founded 2016 Decacorn

← All companies

A public taster of the full Dealroom platform — request a demo to explore live financials, founders, funding history, and market intelligence.

Valuation

$10–50B

Latest valuation · 2026

Unlock exact value

Headcount

<100

Current team size

Unlock exact value

Patent intelligence

$314M patent portfolio · 101 active families

Total estimated portfolio value via Dealroom Patent Intelligence (Patsnap), with quality scores compared against same-sector peers.

Estimated portfolio value

$314M

2.7% of valuation · 6.5× smaller than top peer Ablynx ($2B)

101 active patent families

Where Bioverativ innovates Molecular biologyAntiendomysial antibodiesImmunologyAnti antibodyDisease

Above peer median on Strategic, Market

Quality vs same-sector peers

Bioverativ on the five Patsnap quality dimensions

Bioverativ in orange. Same-sector peers are the top filers by total patent value. All scores 0–100; higher is stronger.

Compare against

Patent quality scores (0–100)

Source: Dealroom Patent Intelligence · Patsnap

Tech-focus vs peers

Where Bioverativ concentrates inside the peer cluster

Axes are the most-shared Patsnap topics across Bioverativ and its top peers. Each polygon's reach on an axis = how prominent that topic is in that company's portfolio (#1 topic = 100, #10 = 10, absent = 0).

Compare against

Top-topic prominence (rank inverted, 0–100)

Source: Dealroom Patent Intelligence · Patsnap top-10 topics per company

This is teaser data. The full per-sub-category breakdown, individual patent records, and quality-score history are on the Dealroom platform — request a demo to access.

See Bioverativ on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Open in Dealroom Book a demo